Clinical data | |
---|---|
Other names | MEDI-0382 |
Routes of administration | Subcutaneous injection |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChemCID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C167H252N42O55 |
Molar mass | 3728.092 g·mol−1 |
3D model (JSmol) | |
| |
|
Cotadutide is an experimental drug for the treatment oftype 2 diabetes mellitus. It lowersblood glucose levels by mimicking the human hormonesglucagon-like peptide 1 andglucagon, which play a role in blood sugar regulation. The drug is apeptide that is injected under the skin.[1][2]
Cotadutide is in Phase IIclinical trials as of February 2021[update].[3] Cotadutide, a therapeutic agent, was undergoing Phase II clinical trials. This stage of trials typically involves evaluating the drug's effectiveness and further assessing its safety in a larger group of participants, compared to earlier phases.[citation needed]
![]() | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
![]() | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |